ABSTRACT: tRNA modifications are crucial for efficient and accurate protein synthesis, and modification defects are frequently associated with disease. Yeast trm7 mutants grow poorly due to lack of 2 -O-methylated C 32 (Cm 32 ) and Gm 34 on tRNA Phe , catalyzed by Trm7-Trm732 and Trm7-Trm734, respectively, which in turn results in loss of wybutosine at G 37 . Mutations in human FTSJ1, the likely TRM7 homolog, cause nonsyndromic X-linked intellectual disability (NSXLID), but the role of FTSJ1 in tRNA modification is unknown. Here, we report that tRNA Phe from two genetically independent cell lines of NSXLID patients with loss-of-function FTSJ1 mutations nearly completely lacks Cm 32 and Gm 34 , and has reduced peroxywybutosine (o2yW 37 ). Additionally, tRNA
Introduction
The numerous post-transcriptional modifications of tRNA are crucial for accurate and efficient translation of the genetic code. In the yeast Saccharomyces cerevisiae, mutations affecting 16 of the 25 tRNA modifications lead to distinct phenotypes, including lethality for three mutants, and poor growth or temperature sensitivity for six other mutants [Hopper, 2013] . Modifications in and around the tRNA anticodon loop (residues 31-39) are particularly important in all organisms [de Crecy-Lagard et al., 2012] , often affecting decoding [Murphy et al., 2004; Agris et al., 2007] , charging by the cognate tRNA aminoacyl synthetase [Muramatsu et al., 1988; Putz et al., 1994] , and/or frame maintenance [Urbonavicius et al., 2001; Bekaert and Rousset, 2005; Waas et al., 2007] , whereas modifications in the body of the tRNA often contribute to folding or stability [Hall et al., 1989; Yue et al., 1994; Helm et al., 1999; Whipple et al., 2011] and are required to avoid decay by two known degradation pathways [Kadaba et al., 2004; LaCava et al., 2005; Vanacova et al., 2005; Alexandrov et al., 2006; Kadaba et al., 2006; Schneider et al., 2007; Chernyakov et al., 2008] .
Emerging evidence shows that tRNA modifications have important roles in human health. Mutations in nine predicted human homologs of tRNA modification genes have been strongly linked to specific diseases, seven of which are linked to neurological disorders, including six linked to intellectual disability (ID) [Anderson et al., 2001; Slaugenhaupt et al., 2001; Cuajungco et al., 2003; Freude et al., 2004; Ramser et al., 2004; Froyen et al., 2007; Takano et al., 2008; Zeharia et al., 2009; Najmabadi et al., 2011; Abbasi-Moheb et al., 2012; Khan et al., 2012; Martinez et al., 2012; Alazami et al., 2013; Igoillo-Esteve et al., 2013; Fahiminiya et al., 2014; Gillis et al., 2014; Yarham et al., 2014] . However, the molecular basis of the link Hu et al. (2015) between the neurological disorders and mutations in predicted tRNA modification genes is not clear. Indeed, decreased levels of tRNA modifications have only been demonstrated in cells derived from patients with two neurological disorders. First, bulk tRNA from brain tissue and cell lines derived from familial dysautonomia (FD) patients, which is due to mutations in IKBKAP in numerous cases [Anderson et al., 2001; Slaugenhaupt et al., 2001; Dong et al., 2002; Cuajungco et al., 2003] , had reduced levels of the mcm 5 s 2 U 34 modification and the IKAP protein [Karlsborn et al., 2014] . This result is consistent with the homology between IKAP and the Elp1 subunit of the S. cerevisiae elongator complex [Hawkes et al., 2002] , which is required for cm 5 U formation [Huang et al., 2005] . Second, tRNA from cells derived from patients with a Dubowitz-like syndrome (characterized by phenotypes including microcephaly and mental and speech delays) linked to an NSUN2 splice-site mutation lacked m 5 C at residues 34, 48, 49, and 50 [Martinez et al., 2012; Blanco et al., 2014] , consistent with the activity of the yeast and mammalian homologs [Motorin and Grosjean, 1999; Brzezicha et al., 2006; Blanco et al., 2011; Tuorto et al., 2012] . NSUN2 mutations are also linked to other neurological disorders including a Noonan-like syndrome similar to the NSUN2-linked Dubowitz-like syndrome [Fahiminiya et al., 2014] and autosomal-recessive ID (ARID) in four independent families [Abbasi-Moheb et al., 2012; Khan et al., 2012] .
One of the strongest links between ID and a putative tRNA modification gene is that linking nonsyndromic X-linked ID (NSXLID) to mutations in FTSJ1 (MIM #300499), a homolog of yeast Trm7, which catalyzes formation of Cm 32 and Nm 34 on substrate tRNAs [Pintard et al., 2002] and is critical for normal function of tRNA Phe [Guy et al., 2012] . Distinct alleles of FTSJ1 from five independent families are linked to NSXLID and each allele results in reduced levels of mRNA or reduced predicted protein function [Freude et al., 2004; Ramser et al., 2004; Takano et al., 2008] . In addition, NSXLID is linked to a microdeletion that removes FTSJ1 and SLC38A5 [Froyen et al., 2007] (Table 1; Supp. Table S1 ). Moreover, FTSJ1 is the likely human ortholog of the yeast TRM7 gene, since expression of human FTSJ1 under control of the strong P GAL promoter (P GAL -FTSJ1) in a high copy (2μ) plasmid suppresses the severe growth defect of S. cerevisiae trm7 mutants [Guy and Phizicky, 2015] .
In S. cerevisiae, Trm7 is the central component of a complex modification circuitry required for anticodon loop modification of target tRNAs, wherein Trm7 separately interacts with Trm732 and Trm734 to form Cm 32 , and Nm 34 , respectively, both of which are required on tRNA Phe for efficient formation of wybutosine (yW) at m 1 G 37 by other proteins (Fig. 1A ) [Noma et al., 2006; Guy et al., 2012] . Moreover, the same circuitry appears to be conserved in the phylogenetically distant yeast Schizosaccharomyces pombe, since the nearly lethal phenotype of trm7 mutants is suppressed by overproduction of tRNA Phe , since tRNA Phe of trm7 mutants likewise lacks Cm 32 , Gm 34 , and yW 37 , and since the homologous S. pombe Trm732 and Trm734 proteins are required for the respective Cm 32 and Gm 34 modifications [Guy and Phizicky, 2015] . Indeed, this conserved circuitry might be further extended in eukaryotes since suppression of the growth defect of S. cerevisiae trm7 mutants by FTSJ1 expression requires the function of Trm732 or its human homolog THADA to form Cm 32 on tRNA
Phe [Guy and Phizicky, 2015] .
Although it is well established that human FTSJ1 mutations cause NSXLID, the connection between FTSJ1 and tRNA modifications is not known in human cells, or in any metazoan. Indeed, it is not necessarily true that FTSJ1 modifies human tRNAs based on complementation of a yeast mutant when FTSJ1 is expressed at high levels.
Here, we show that cell lines derived from NSXLID patients bearing genetically distinct disease-causing FTSJ1 mutations have pronounced defects in 2'-O-methylation of the anticodon loop of tRNAs, with reduced levels of peroxywybutosine (o2yW 37 ) on tRNA Phe . These findings provide strong evidence that FTSJ1 catalyzes Cm 32 and Nm 34 modification in humans, and further support the conserved circuitry for tRNA Phe anticodon loop modification. Intriguingly, tRNA
Phe from human cell lines with a novel missense FTSJ1-p.A26P mutation (NM 012280.2, c.76G>C, p.A26P; nucleotide numbering is based on cDNA sequence) or from the corresponding yeast trm7-A26P mutant lacks Gm 34 but retains Cm 32 , apparently due to selective loss of substrate recognition and/or catalysis, rather than to reduced expression or protein interactions. These results strongly suggest that FTSJ1-associated NSXLID is due to lack of modifications of the anticodon loop of substrate tRNAs, and suggest the possibility that if tRNA Phe is the important human FTSJ1 target (as is true in two phylogenetically distant model yeast organisms), that lack of only Gm 34 of tRNA Phe might be sufficient to trigger NSXLID.
Materials and Methods

Sequencing and Identification of the FTSJ1-p.A26P Variant
DNA extracted from whole-blood (QIAamp DNA blood maxi kit; Qiagen, Limburg, The Netherlands) was part of a large Xchromosome exome sequencing study [Hu et al., 2015] , with one affected individual sequenced from this family (III-2, HiSeq; Illumina, San Diego, CA). Confirmation of the FTSJ1 gene (NM 012280.2, c.76G>C, p.A26P; nucleotide numbering based on cDNA sequence) variant and segregation analysis by Sanger sequencing was carried out using standard methods. FTSJ1 exon 2 DNA was amplified and sequenced using the following primers; F -5 -GCA GTG GAG CCT GAG AGT TC-3 and R -5 -CTA TCT TCC TGC CTG TCT CCC T-3 .
Generation of Lymphoblastoid Cell Lines
Lymphoblastoid cell lines (LCLs) derived from patients bearing a c.121+1delG mutation in FTSJ1 (Table 1; Supp. Table S1 ; FTSJ1-ss; family 3), and from a patient bearing an FTSJ1 deletion (FTSJ1 ; family 6) have been described previously [Freude et al., 2004; Froyen et al., 2007] . Other LCLs were generated using standard methods.
Yeast Strains and Plasmids
Yeast strains are listed in Supp. 
tRNA Purification and Northern Blot Analysis
For a detailed description of cell growth conditions and RNA preparation, see Supp. Methods. Briefly, RNA from LCLs was extracted using TRIzol (Life Technologies, Carlsbad, CA) according to manufacturer's instructions. Extraction of RNA using phenol for northern analysis under acidic conditions to preserve aminoacylation was previously described [Alexandrov et al., 2006] . Low molecular weight RNA was extracted from yeast cells as previously described [Jackman et al., 2003] , and appropriate 5' biotinylated oligonucleotides were used to purify tRNA from yeast and human RNA preparations as previously described [Jackman et al., 2003] .
HPLC Analysis of tRNA
Purified tRNA was digested with P1 nuclease and phosphatase as previously described [Jackman et al., 2003] , and nucleosides were subjected to HPLC analysis essentially as previously described [Jackman et al., 2003] . Nucleosides from tRNA Phe were separated by HPLC at pH 7.0 to maximize separation of Gm and m 1 G, as previously described [Guy et al., 2012] , and o2yW was separated by HPLC as previously described [Noma et al., 2006] .
Immunoblot Analysis
Yeast crude extracts were subjected to SDS-PAGE and proteins were transferred to nitrocellulose membrane (Bio-Rad, Hercules, CA). MORF-tagged and PT-tagged constructs were detected with rabbit polyclonal antiprotein A (1:5,000; Sigma-Aldrich, St. Louis, MO.), followed by incubation with goat antirabbit IgG-HRP (1:10,000; Bio-Rad), and visualization with Amersham ECL Plus (GE Healthcare, Little Chalfont, Buckinghamshire, UK). The 9myc tag was detected with mouse monoclonal anti- [c-myc] (1:10,000; Roche, Basel, Switzerland), followed by incubation with goat antimouse IgG-HRP (1:10,000; Bio-Rad), and visualization. 
Affinity Purification of Tagged Proteins
MORF-tagged and PT-tagged proteins were purified by affinity purification with IgG Sepharose followed by elution with GST-3C protease, and removal of the protease using glutathione Sepharose resin, essentially as previously described [Quartley et al., 2009] .
Clinical Description
For a detailed clinical description, see Supp. Methods. This research was approved by the Women's and Children's Health Network Human Research Ethics Committee.
Results
FTSJ1 Is Required for Cm 32 and Gm 34 Modification of tRNA Phe
To determine whether patients with FTSJ1-associated NSXLID have reduced 2 -O-methylation in their tRNAs, we analyzed tRNA Phe purified from LCLs derived from a patient with an X-chromosome microdeletion of FTSJ1 and SLC38A5 (FTSJ1 , family 6; Table 1 ; Supp. Table S1 ) [Froyen et al., 2007] and from two brothers with a splice-site mutation in FTSJ1 (c.121+1delG, FTSJ1-ss, family 3; Table  1 ; Supp. Table S1 ) [Freude et al., 2004] , as well as from two control LCLs derived from healthy individuals. We found that tRNA Phe purified from the FTSJ1 LCL had no detectable Cm or Gm modification (<0.03 moles/mole for each vs. 0.72-0.74 moles/mole for Cm and 0.69-0.74 moles/mole for Gm), and that tRNA Phe from both of the FTSJ1-ss LCLs had undetectable Gm and a small, but detectable, amount of Cm (0.07 and 0.05 moles/mole, respectively), whereas levels of , m 5 C, m 1 A, m 7 G, and m 2 G were similar to those from control LCLs [ Table 2 ; Fig. 1B and C). Thus, these data strongly indicate that FTSJ1 is the homolog of yeast TRM7 that is responsible for 2 -O-methylation of tRNA Phe in humans, and link FTSJ1-associated NSXLID with tRNA modification defects.
We also found that FTSJ1 and FTSJ1-ss LCLs have reduced levels of the o2yW modification of m 1 G 37 of tRNA Phe . Thus, we observed an increase in m 1 G on tRNA Phe from LCLs with these FTSJ1 mutations compared with control LCLs (0.65-0.74 moles/mole, compared with 0.15-0.42 moles/mole; Table 2 Table 2 ; Fig. 1D ). This result implies that, as for yW 37 formation in both S. cerevisiae and S. pombe [Guy et al., 2012; Guy and Phizicky, 2015] , o2yW 37 formation from m 1 G is stimulated by Cm 32 and/or Gm 34 of tRNA Phe .
We also analyzed Cm levels on tRNA Trp , which has Cm 32 and Cm 34 in five of six characterized tRNA Trp species from eukaryotes [Machnicka et al., 2013; Guy and Phizicky, 2015] , including the mammal Bos taurus [Fournier et al., 1978] and is modified at both residues by Trm7 in S. cerevisiae [Pintard et al., 2002] . Since tRNA Trp purified from the FTSJ1 LCL lacked Cm, whereas tRNA
Trp from a control LCL had substantial amounts of Cm (<0.03 vs. 1.06 moles/mole; Supp. Table S4 ), we infer that tRNA
Trp is modified by FTSJ1 in humans.
As in yeast [Guy et al., 2012] , the lack of modification in LCL tRNAs that is due to FTSJ1 mutations does not appear to affect the amounts or the charging levels of substrate tRNAs. Thus, levels of tRNA Phe and tRNA Trp from LCLs with FTSJ1-ss or FTSJ1 mutations appear to be normal relative to wild-type LCLs, as determined by Northern blot analysis (Supp. Fig. S1 ). Furthermore, lack of these modifications does not appear to affect tRNA charging in these cells, since there is as much or more charged tRNA Phe and tRNA Trp relative to uncharged tRNA in the mutant LCLs as in the wild-type LCLs (Supp. Fig. S1 ).
Identification of a Novel, Missense FTSJ1 Variant c.76G>C; p.A26P in a Family with NSXLID
By investigation of the X-chromosome exome of a proband (III-2) from a large multigenerational family with NSXLID ( Fig. 2A ; Table 1; Supp. Table S1 ; family 7, see Materials and Methods and Hu et al., 2015) , we identified a novel FTSJ1 variant c.76G>C, p.A26P (RefSeq NM 012280.2). Subsequent sequencing analysis of six other available family members showed that the c.76G>C; p.A26P allele segregates with ID ( Fig. 2A; Supp. Fig. S2 ). The c.76G>C; p.A26P allele is not currently present in the Exome Variant Server, ExAC Browser, or SNP database from the UCSC genome browser. This variant was submitted to the Leiden Open Variation Database (http://www.lovd.nl/FTSJ1).
Based on the fact that the FTSJ1-p.A26P allele was unique, segregated with ID in the pedigree, and is in a highly conserved region of the FTSJ1/Trm7 protein family (Fig. 2B) , we predicted that this allele was deleterious to FTSJ1 protein function, thus causing ID in this family, consistent with previous studies linking loss of function FTSJ1 mutations and NSXLID [Freude et al., 2004; Ramser et al., 2004; Froyen et al., 2007; Takano et al., 2008] . Indeed, the FTSJ1-p.A26P variant might also be expected to have impaired methyltransferase activity because p.A26 of FTSJ1 is only two residues from the predicted catalytic residue p.K28 in the same predicted α-helix, based on the structure of the FtsJ protein family member RrmJ (Fig. 2C) [Bugl et al., 2000; Pintard et al., 2002; Feder et al., 2003 ]. Amino acid sequence alignment of the N-terminal region of human FTSJ1 with known or predicted Trm7 proteins from diverse eukaryotes. Residue A26 is indicated by magenta arrow, and other residues analyzed in this study are indicated by black arrows. C: Predicted location of A26 residue of FTSJ1, based on the Escherichia coli RrmJ crystal structure. Representation of E. coli RrmJ (PDB 1EIZ), with catalytic triad residues in cyan, corresponding human FTSJ1 residues in round brackets, and corresponding S. cerevisiae residues in square brackets. Trp36 of RrmJ (corresponding to FTSJ1 p.A26) is magenta, and the predicted α-helix containing A26 (residues 33-46 of RrmJ) is dark gray.
The FTSJ1-p.A26P Variant Results in tRNA
Phe Lacking Only Gm 34 Consistent with a decrease in FTSJ1 activity, tRNA
Phe from an LCL derived from the proband III-2 ( Fig. 2A) with the FTSJ1-p.A26P allele had undetectable Gm (Table 2 ; Fig. 1B and C) ; however, this tRNA Phe had nearly normal Cm levels (0.63 moles/mole vs. 0.72-0.74 moles/mole in control LCLs with wild-type FTSJ1), and o2yW 37 levels (0.80 relative to 1.0 and 0.6 from two control LCLs; Table 2 ; Fig. 1D ). The FTSJ1-p.A26P LCL was also defective for modification of tRNA Trp with low, but detectable levels of Cm modification for the sample that was analyzed (0.15 vs. 1.06 moles/mole; Supp. [Guy and Phizicky, 2015] ; however, no complementation was observed upon expression of the FTSJ1-p.A26P variant, since growth on FOA was similar to that of the trm7 mutant bearing the vector or expressing the presumed catalytically dead variants FTSJ1-p.K28A or FTSJ1-p.K158A (Fig. 3A) [Feder et al., 2003 ]. We note, however, that levels of an affinity tagged FTSJ1-p.A26P-PT variant (for a description of the PT tag, see Supp. Methods) were reduced about 10-fold relative to those of FTSJ1-PT or the FTSJ1-p.K28A-PT variant (Supp. Fig. S3 ), suggesting that lack of complementation in yeast could be due, in part, to reduced protein levels.
However, we found that expression of S. cerevisiae trm7-A26P complements the growth defect of a trm7 mutant, with similar effects on tRNA Phe modification as in the human FTSJ1-p.A26P LCL. Thus, a [CEN LEU2 P TRM7 -trm7-A26P] plasmid fully complemented a trm7 mutant, whereas no complementation was observed with plasmids expressing the predicted catalytic dead variants trm7-K28A or trm7-K164A (Fig. 3A) Phe by Trm7-A26P, introduction of a [CEN LEU2 P TRM7 -trm7-A26P] plasmid fully suppressed the slow growth of a trm7 trm734 mutant, but only partially suppressed the slow growth of a trm7 trm732 mutant over a range of temperatures from 18°C to 37°C (Fig. 3C) .
To further characterize in vivo activity of the Trm7-A26P variant, we examined modifications of the other S. cerevisiae Trm7 sub- variants as indicated were grown overnight in S-Leu medium containing raffinose and galactose, diluted to OD 600 of ß0.5 in H 2 O, and serially diluted 10-fold in H 2 O, and then 2 μL was spotted onto S medium containing raffinose, galactose, and 5-FOA, followed by incubation for 3 days at 30°C. B: An S. cerevisiae trm7 mutant expressing trm7-A26P from a low copy (CEN) plasmid efficiently forms Cm 32 , but not Gm 34 on tRNA Phe . Quantification of nucleosides from tRNA Phe isolated from indicated yeast strains. * , levels below threshold of detection. C: A CEN plasmid expressing trm7-A26P does not fully suppress the slow growth of S. cerevisiae trm7 trm732 mutants. Wild type, trm7 , trm7 trm732 , and trm7 trm734 strains with [CEN URA3 P TRM7 -TRM7] and [LEU2] plasmids as indicated were grown overnight in SD-Leu, diluted, plated on SD-Leu medium containing 5-FOA, and incubated for 2 days at 30°C to select for loss of the URA3 plasmid (top panel), followed by growth analysis on YPD at the indicated temperatures (bottom panel). . Table S6 ). This finding may suggest that the Trm7-A26P variant has retained some specificity for C 32 modification, while losing specificity for N 34 modification, regardless of base identity. As expected, the catalytic dead Trm7-K28A variant and the presumed catalytic dead Trm7-K164A variant lacked the ability to 2'-O-methylate tRNA Leu(UAA) or tRNA Trp (Supp. Tables S5 and S6). Our finding that the Trm7-A26P variant fully suppresses the growth defect of trm7 mutants, but only substantially modifies C 32 of tRNA Phe (and not other tRNAs), is consistent with our previous findings that only Cm 32 or Gm 34 modification of tRNA Phe is required for healthy growth in S. cerevisiae [Guy et al., 2012] .
Overexpression of S. Cerevisiae Trm7-A26P Does Not Restore Full Gm 34 Modification Levels on tRNA Phe
Although expression of Trm7-A26P on a [CEN LEU2 P TRM7 -trm7-A26P] plasmid fully complemented the growth defect of a trm7 mutant, expression levels of the corresponding C-terminally affinity-tagged Trm7-A26P-MORF variant (for a description of the MORF tag, see Materials and Methods) were reduced to ß1/3 the levels observed from corresponding strains expressing wild-type Trm7-MORF or the Trm7-K28A-MORF variant (Supp. Fig. S4 ). Thus, it was possible that the selective loss of Gm 34 on tRNA Phe in the trm7 [CEN LEU2 P TRM7 -trm7-A26P] mutant was due to reduced Trm7-A26P. Alternatively, it might be due to reduced interaction of Trm7-A26P with Trm734, since Trm7 forms a distinct complex with Trm734, and both proteins are required for Nm 34 formation in S. cerevisiae [Guy et al., 2012] .
To test whether there was a reduced interaction between Trm7-A26P and Trm734, we transformed CEN plasmids expressing TRM7-MORF or trm7-A26P-MORF into TRM732-9myc or TRM734-9myc yeast strains, and then purified the Trm7 using the tag. Both Trm732-9myc and Trm734-9myc copurified with Trm7-MORF and with Trm7-A26P-MORF with comparable efficiency, after taking into account the reduced expression of Trm7-A26P ( Fig. 4A and B) .
To further probe the selective loss of Gm 34 on tRNA Phe in the trm7 strain expressing trm7-A26P, we overexpressed Trm7-A26P and examined the interaction with Trm734 and Gm levels of tRNA Phe . Immunoblot analysis against the ZZ domain of protein A demonstrated that expression of Trm7-A26P-PT (the PT tag has identical components as the MORF tag, see Supp. Methods) from a 2μ P GAL plasmid ([2μ URA3 P GAL -trm7-A26P-PT]) resulted in more than a 125-fold increase in Trm7-A26P levels, compared with wild-type Trm7-MORF expressed from a [CEN URA3 P TRM7 -TRM7-MORF] plasmid (Fig. 4C) . Furthermore, purification of overexpressed Trm7-A26P-PT resulted in pulldown of ß10-fold more Trm734-9myc than was pulled down during purification of Trm7-MORF expressed from the [CEN URA3 P TRM7 -TRM7-MORF] plasmid. However, despite the >125-fold overexpression and the ß10-fold increase in Trm734 pull down, Gm 34 formation on tRNA Phe was not fully restored by overexpression of either tagged Trm7-A26P from the [2μ LEU2 P GAL -TRM7-A26P-PT] plasmid or untagged Trm7-A26P from the otherwise identical [2μ LEU2 P GAL -TRM7-A26P] plasmid (Table 3) . Indeed, under these conditions, overexpression of untagged Trm7-A26P in the trm7 strain resulted in only 0.26 moles/mole Gm on tRNA Phe . Consistent with this finding, overexpression of trm7-A26P also failed to fully suppress the growth defect of a trm7 trm732 mutant (Fig. 4D) .
We note that the C-terminal tag of Trm7-PT or Trm7-MORF appears to interfere with Gm formation, since Gm modification of tRNA Phe was reduced from 0.88 to 0.50 moles/mole in a trm7 [CEN LEU2 P TRM7 -TRM7-MORF] strain relative to a trm7 [CEN P TRM7 -LEU2 TRM7] strain (Table 3) , and similar results were observed when TRM7 had a C-terminal c-myc tag (data not shown). This loss of Gm modification is even more extreme in the corresponding strains expressing Trm7-A26P-MORF or Trm7-A26P-PT. Nonetheless, we conclude that the loss of Gm 34 modification activity in the Trm7-A26P variant is not due to a Trm734 binding defect, since overexpression of Trm7-A26P-PT results in more pulldown of Trm734 than occurs with wild-type Trm7-MORF expressed from a CEN plasmid, whereas overexpression of even untagged Trm7-A26P (presumably resulting in the same or more Trm7 than with tagged Trm7) does not fully rescue Gm 34 modification of tRNA Phe (Table 3 ). expressed from a CEN plasmid efficiently forms a complex with chromosomally expressed Trm732-9myc. Crude extracts were prepared from the indicated strains grown in SD-Leu medium, and proteins were purified with IgG-Sepharose beads (which binds the ZZ domain of the MORF tag), followed by treatment with 3C protease, as described in Materials and Methods, and then samples were analyzed by SDS-PAGE and immunoblot analysis as indicated. B: Trm7-A26P-MORF expressed from a CEN plasmid forms a complex with chromosomally expressed Trm734-9myc. Samples were analyzed as in panel A. C: Trm7-A26P-PT expressed from a high copy (2 μ) plasmid forms more Trm7-A26P:Trm734-9myc complex than the corresponding Trm7:Trm734-9myc complex in wild-type cells. Indicated samples grown in S-Leu medium containing raffinose and galactose were analyzed as in panel A. D: Overexpressed TRM7-A26P does not fully suppress the slow growth of S. cerevisiae trm7 trm732 mutants. Wild-type and trm7 trm732 strains with plasmids as indicated were grown overnight in S-Leu medium containing raffinose and galactose as in Figure 3A , and spotted to the indicated media.
Overexpression of untagged Trm7-A26P also appeared to result in a modest but limited increase in Cm levels on tRNA Trp purified from trm7 mutants (from 0.13 to 0.31 moles/mole; Supp. Table S7) , and modest increases in Cm and ncm 5 Um levels in tRNA Leu(UAA) (Supp .  Table S8 ). Thus, all modification defects associated with normal expression of Trm7-A26P appear to persist even when Trm7-A26P is massively overproduced.
Other Mutations in the Predicted α-Helix Bearing A26 of Trm7 Result in tRNA
Phe Specifically Lacking Gm 34 We investigated the roles of other Trm7 residues in the region near residue A26 because of its proximity to the catalytic residue K28 and because of the intriguing observation that Trm7-A26P efficiently forms Cm 32 , but not Gm 34 , on tRNA Phe . We constructed [CEN LEU2 P TRM7 -TRM7] plasmids expressing Trm7 variants bearing other amino acid substitutions at A26, and substitutions in the predicted α-helix bearing A26 (which encompasses residues 23-36, based on E. coli RrmJ [Bugl et al., 2000 ]), and then tested their ability to suppress the growth defects of trm7 , trm7 trm732 , and trm7 trm734 mutants. We found that expression of the trm7-A26W or trm7-A26G variant resulted in complete complementation of the growth defect in all three strain backgrounds, whereas expression of trm7-A26E resulted in a distinct growth defect only in the trm7 trm732 strain at 30°C (Fig. 5A) , similar to the phenotype resulting from the trm7-A26P variant, although there was also a minor growth defect in the trm7 and trm7 trm734 backgrounds that was more obvious at 18°C. Consistent with this result, we found that tRNA Phe from the trm7 [CEN LEU2 P TRM7 -trm7-A26E] strain had undetectable Gm levels and about 50% of the normal Cm levels (0.54 vs. 1.00 moles/mole), whereas Cm and Gm of tRNA Phe were at near normal levels in the trm7 [CEN LEU2 P TRM7 -trm7A26W] strain (1.03 and 0.54 moles/mole, respectively, compared with 1.0 and 0.81 moles/mole in wild type; Supp. Table S9 ).
Similar to our observations with the trm7-A26P and trm7-A26E variants, we found that expression of a trm7-L32P variant resulted in a growth defect specifically in the trm7 trm732 strain, and not in the trm7 or trm7 trm734 strains (Fig. 5A) , and that tRNA
Phe from the trm7 [CEN LEU2 P TRM7 -trm7-L32P] strain had barely detectable Gm (0.03 moles/mole) but nearly normal levels of Cm (0.90 moles/mole) (Supp. Table S9 ). By contrast, expression of the trm7-L32A variant complemented the growth defect of all three strains and yielded normal tRNA Phe modifications ( Fig. 5A ; Supp. Table S9 ), whereas expression of trm7-A23P, trm7-R24A, or trm7-R24P variants resulted in no complementation in any strain background, suggesting lack of function for these variants.
Thus, these results demonstrate that Trm7 variants with other mutations at A26 or elsewhere in the helix specifically lose the ability to form Gm 34 on tRNA Phe while retaining Cm 32 modification ability.
Discussion
In this report, we have provided strong evidence that human FTSJ1 is required for Cm 32 and Gm 34 modification of tRNA Phe , since these tRNA Phe modifications were undetectable, or drastically reduced, in each of three LCLs derived from NSXLID patients with two distinct FTSJ1 loss of function mutations, whereas tRNA Phe from each of two control cell lines derived from healthy individuals with wild-type FTSJ1 had essentially normal Cm and Gm levels. Since we also observed parallel selective loss of Gm in tRNA Phe from the FTSJ1-p.A26P LCLs and from the S. cerevisiae trm7-A26P mutant (Fig. 5B) , and since expression of FTSJ1 complements the growth defect of an S. cerevisiae trm7 mutant by forming Cm 32 on tRNA Phe [Guy and Phizicky, 2015] , we conclude that FTSJ1 catalyzes formation of Cm and Gm on tRNA Phe in human cells. Furthermore, since FTSJ1 mutant alleles segregate with NSXLID in each of the previously reported families from which the LCLs were derived [Freude et al., 2004; Froyen et al., 2007] , in the new family with the p.A26P variant reported here, as well as in four other reported families [Freude et al., 2004; Ramser et al., 2004; Takano et al., 2008] and likely in an additional family [Hu et al., 2015] , we conclude further that defective 2'-O-methylation of N 32 and N 34 of the anticodon loop of substrate tRNAs is a major contributing factor in FTSJ1-associated NSXLID.
FTSJ1 mutations might contribute to NSXLID through lack of modification of any FTSJ1 tRNA substrate. Indeed, we provided evidence that FTSJ1 modifies tRNA Trp in LCLs, and Cm modification of this tRNA was severely reduced in FTSJ1-p.A26P LCLs. Moreover, it is possible that FTSJ1 modifies any of the four other documented human tRNA species with Nm 32 and/or Nm 34 [Machnicka et al., 2013] , or any of the numerous uncharacterized tRNAs, and hypomodification of any of these tRNAs could contribute to ID. However, we speculate that defective 2'-O-methylation of tRNA Phe may play a major role in ID, for two reasons. First, reduced function of tRNA Phe is the major cause of the slow growth defect of S. cerevisiae and S. pombe trm7 mutants [Guy et al., 2012; Guy and Phizicky, 2015] . Second, the tRNA Phe anticodon loop 2'-O-methylations are very highly conserved, since each of the 17 eukaryotic tRNA Phe species that have been characterized has Cm 32 , and 16 of the 17 also have Gm 34 [Machnicka et al., 2013] . If lack of tRNA Phe modification by FTSJ1 is a major contributor to NSXLID, then it would follow that the defective tRNA Phe would primarily be due to lack of Gm 34 , because levels of both Cm 32 and o2yW 37 are normal in the FTSJ1-p.A26P LCL. This importance of Gm 34 of tRNA Phe would be consistent with the finding in S. pombe that Gm 34 of tRNA Phe is much more important for function than Cm 32 , as measured by growth phenotypes of mutants [Guy and Phizicky, 2015] . We note that NSXLID patients with the FTSJ1-p.A26P mutation appear to have ID comparable to that of other FTSJ1-associated NSXLID patients (Supp. Table S1), although there have not been any direct, objective comparisons of the extent of ID for each of the NSXLID patients.
These results also underscore the conservation of the intricate circuitry for anticodon loop modification of tRNA Phe , as tRNA Phe from LCLs of patients with splice site and null alleles of FTSJ1 had significantly reduced levels of o2yW 37 , compared with control LCLs, accompanied by increased levels of the o2yW precursor m 1 G. This result suggests that the o2yW 37 modification may be dependent on Cm 32 and Gm 34 modification, as is the yW 37 modification in S. cerevisiae and S. pombe [Guy et al., 2012; Guy and Phizicky, 2015] . However, unlike in these yeast species, lack of FTSJ1 in human LCLs did not completely abrogate o2yW modification of tRNA Phe , lack of Gm 34 did not appear to affect o2yW 37 levels, and control LCLs had variable levels of o2yW, accompanied by correspondingly variable m 1 G levels. The apparent dependence of o2yW 37 on Cm 32 and Gm 34 is consistent with previous observations that tRNA Phe from neuroblastoma cells and a fraction of tRNA Phe from Ehrlich ascites cell lines lack Cm, Gm, and o2yW [Kuchino et al., 1982] , although it is not clear why tRNA Phe was affected in these cell lines. It is intriguing that both human FTSJ1-p.A26P and yeast Trm7-A26P are specifically defective in Gm 34 modification of tRNA Phe , while retaining normal levels of Cm 32 modification. Since our data indicate that overproduction of Trm7 by more than 125-fold can rescue the minor defect in Trm734 binding but not the Gm modification defect, this result suggests that the Trm7-A26P defect is due to some specific aspect of substrate recognition or catalysis for Gm 34 modification. This interpretation is consistent with the location of residue 26 near the catalytic residue K28 [Pintard et al., 2002; Feder et al., 2003] . Alternatively, G 34 of tRNA Phe may simply be more difficult to modify than C 32 , and the p.A26P mutation might cause a general loss in methylation activity. This interpretation is consistent with the observation that tRNA Phe from FTSJ1-ss LCLs have distinct but low levels of Cm and no detectable Gm, perhaps suggesting a low level of correct mRNA splicing [Freude et al., 2004] . Moreover, Cm 32 of tRNA Phe appears to be the most efficient Trm7 modification target in yeast since overproduction of the Trm7-A26P variant only results in partial modification of C 32 and N 34 of tRNA Trp and tRNA Leu(UAA) , whereas C 32 of tRNA Phe is normally modified even when Trm7-A26P is expressed at normal levels. The observation that yeast trm7 mutants expressing Trm7-A26E or Trm7-L32P at normal levels also selectively modify C 32 , but not G 34 , of tRNA Phe emphasizes the sensitivity of the crucial Gm 34 modification to perturbations in this helix, but leaves unresolved the mechanism by which this occurs. Since FTSJ1-associated NSXLID patients have no consistent dysmorphic, metabolic, or neuromuscular manifestations of the condition other than ID, it would follow that the functional levels of substrate tRNAs are insufficient for brain development and/or cognitive function, but are sufficient in other tissues and other aspects of development. Although little is known about the differential expression of the 450 tRNA genes in the human genome, comprising ß270 isodecoders (which share an anticodon but have a different tRNA body) [Goodenbour and Pan, 2006; Chan and Lowe, 2009] , there is evidence that an isodecoder can be specifically expressed in the central nervous system [Ishimura et al., 2014] . A role for FTSJ1 in neurological development is consistent with the observation that expression of FTSJ1 mRNA in the fetus is highest in the brain compared with other tissues tested [Freude et al., 2004] .
The linkage between tRNA modifications and NSXLID reported here is part of an emerging theme linking tRNA modifications and neurological function. Previous studies have directly linked defective m 5 C modification to a Dubowitz-like syndrome [Martinez et al., 2012; Blanco et al., 2014] , and defective cm 5 U modification to FD [Anderson et al., 2001; Karlsborn et al., 2014] , and lesions in four other predicted or likely tRNA modification genes have been linked to neurological function. Thus, lesions in the TRMT10A gene, a homolog of yeast TRM10 [Jackman et al., 2003] , are linked to short stature, microcephaly, and defects in glucose homeostasis and diabetes, and the purified protein corresponding to a missense allele lacks tRNA m 1 G 9 methyltransferase activity [Igoillo-Esteve et al., 2013; Gillis et al., 2014] . Additionally, a missense allele of human ADAT3, the likely homolog of yeast TAD3, required for deamination of A 34 to I 34 [Gerber and Keller, 1999] , is linked to strabismus and ARID [Alazami et al., 2013] ; a frameshift mutation in human TRMT1, the homolog of yeast TRM1, required for m 2,2 G 26 activity [Liu and Straby, 2000] , is linked to ARID [Najmabadi et al., 2011] ; and two distinct missense alleles of human ELP2, a member of the ELP complex [Hawkes et al., 2002; Huang et al., 2005] , are linked to ARID [Najmabadi et al., 2011] . In addition, allelic variants in the human ELP3 gene have been linked by genome-wide association studies to amyotrophic lateral sclerosis, and Elp3 mutants were identified in an accompanying screen for defective neuronal function in Drosophila [Simpson et al., 2009] . We note also that tRNA mutations leading to defects in taurine modifications are implicated in MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) and MERFF (myoclonic epilepsy with raggedred fibers) [Yasukawa et al., 2000a; Yasukawa et al., 2000b; Suzuki et al., 2002] , whereas a TRIT1 mutation resulting in reduced i 6 A modification is linked to myoclonic epilepsy associated with encephalopathy [Yarham et al., 2014] .
Since lack of modifications is often overcome by increased dosage of one or more of the unmodified tRNAs [Esberg et al., 2006; Phizicky and Alfonzo, 2010; Guy et al., 2012; Fernandez-Vazquez et al., 2013; Han et al., 2015] , the numerous links between tRNA modifications and neurological defects suggest that the available pool of functional tRNAs may somehow be limited during development and function of the central nervous system, presumably leading to defects in translation or its regulation [Begley et al., 2007; Chan et al., 2012] . The specific mechanisms by which defects in tRNA biology impact neurological function remain to be determined.
